A newly published peer-reviewed analysis of two major tirzepatide trials found that the active ingredient in Mounjaro and Zepbound doesn't just reduce weight — it moves people into lower BMI categories and meaningfully improves heart-related risk factors. For the millions of people using or considering these medications, the findings add important cardiovascular context to what the drug can do.
What the Research Examined
The study is a post hoc analysis drawing on data from the SURMOUNT-1 and SURMOUNT-4 clinical trials, both of which evaluated tirzepatide in people with obesity. Published in the American Journal of Preventive Cardiology, the analysis looked specifically at whether tirzepatide treatment caused participants to shift between BMI classifications — for example, moving from Class III obesity (BMI ≥ 40) down to Class II or lower — and what those shifts meant for cardiometabolic risk factors like blood pressure, blood sugar, and cholesterol.
Tirzepatide is a dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved in the United States for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea, according to the source material.
Why BMI Category Shifts Matter
Obesity is classified in tiers — and the tier a person sits in carries real clinical consequences. Higher BMI categories are associated with greater risk of heart disease, stroke, type 2 diabetes, and other serious conditions. When a medication moves someone from one BMI category to a lower one, it can signal a meaningful reduction in long-term health risk, not just a number on a scale.
The researchers specifically framed obesity as a chronic disease that results in increased morbidity and mortality if left untreated — language that reinforces why sustained, measurable weight reduction matters clinically, not just cosmetically.
Key takeaway: This analysis suggests tirzepatide doesn't just reduce weight on paper — it can move people into lower-risk BMI categories, with accompanying improvements in the cardiometabolic markers that predict heart disease and diabetes outcomes.
What This Means for Patients on Mounjaro or Zepbound
If you are currently taking tirzepatide for obesity, this research supports the idea that the weight loss you experience may translate into real reductions in cardiovascular risk — not just aesthetic change. Improvements in cardiometabolic risk factors such as blood pressure, lipids, and blood glucose are associated with lower rates of heart attack, stroke, and metabolic disease over time.
Because this is a post hoc analysis, it is important to understand its limitations: post hoc analyses examine existing trial data through a new lens, rather than testing a pre-specified hypothesis from the start. The findings are compelling but should be considered alongside prospective cardiovascular outcome trial data as it emerges.
What to Watch Next
The cardiovascular story for tirzepatide is still developing. Dedicated cardiovascular outcomes trials will provide stronger evidence on whether the BMI and risk-factor improvements seen here translate into fewer actual heart attacks and strokes over time. Patients and clinicians should watch for further publications from the SURMOUNT program and related research as the evidence base matures.
Frequently Asked Questions
This research offers encouraging evidence that tirzepatide's weight-loss effects may carry meaningful heart health benefits — but every patient's situation is unique. Speak with your prescriber or care team to understand what the latest science means for your personal treatment plan.
- Peer-reviewed journal article, 'Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials,' American Journal of Preventive Cardiology, date not specified in source material.